Carbohydrate sulfotransferases: novel therapeutic targets for inflammation, viral infection and cancer.

Abstract:

:Effective direct inhibition of adhesion receptors by small molecules has been hampered by extended receptor-ligand interfaces as well as the entropic penalties often associated with inhibition of cell adhesion. Therefore, alternative strategies have targeted enzymes that are centrally involved in the biosynthesis of recognition epitopes, which are crucial for productive adhesion. Two classes of enzymes shown to play a pivotal role in cell-cell and cell-matrix adhesions are the protein-tyrosine and carbohydrate sulfotransferases, which impart crucial sulfate moieties onto glycoproteins. The carbohydrate sulfotransferases will be discussed in terms of target validation and small-molecule inhibitor discovery.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Hemmerich S

doi

10.1016/s1359-6446(00)01581-6

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

27-35

issue

1

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(00)01581-6

journal_volume

6

pub_type

杂志文章
  • Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes.

    abstract::The global burden of herpes simplex virus (HSV) legitimates the critical need to develop new prevention strategies, such as drugs and vaccines that are able to fight either primary HSV infections or reactivations. Moreover, the ever-growing number of patients receiving transplants increases the number of severe HSV in...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.03.003

    authors: Clementi N,Criscuolo E,Cappelletti F,Burioni R,Clementi M,Mancini N

    更新日期:2016-04-01 00:00:00

  • Progress in the discovery and development of glutamate carboxypeptidase II inhibitors.

    abstract::During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.07.010

    authors: Tsukamoto T,Wozniak KM,Slusher BS

    更新日期:2007-09-01 00:00:00

  • Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

    abstract::Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). Development of IND/GLY was driven by the need to improve the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.015

    authors: Banerji D,Fogel R,Patalano F

    更新日期:2018-01-01 00:00:00

  • Chemoproteomics-driven drug discovery: addressing high attrition rates.

    abstract::The advent of multiple high-throughput technologies has brought drug discovery round almost full circle, from pharmacological testing of compounds in vivo to engineered molecular target assays and back to integrated phenotypic screens in cells and organisms. In the past, primary screens to identify new pharmacological...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.04.014

    authors: Hall SE

    更新日期:2006-06-01 00:00:00

  • 'Big Data' informed drug development: a case for acceptability.

    abstract::Data, which help inform various stages of drug product development, are increasingly being collected using newer, more novel platforms, such as mobile applications, and analysed computationally as much larger 'Big Data' data sets, revealing patterns relating to human behaviour and interactions. Medicine acceptability ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.12.011

    authors: Desai N,Edwards AJ,Ernest TB,Tuleu C,Orlu M

    更新日期:2020-12-24 00:00:00

  • The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.

    abstract::The stratified medicine companion diagnostic (CDx) cut-off decision integrates scientific, clinical, ethical, and commercial considerations, and determines its value to developers, providers, payers, and patients. Competition already sharpens these issues in oncology, and might soon do the same for emerging stratified...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.10.017

    authors: Trusheim MR,Berndt ER

    更新日期:2015-12-01 00:00:00

  • Impact of new technologies for cellular screening along the drug value chain.

    abstract::High-information screening formats, using more physiologically relevant cellular models and readout approaches, are slowly replacing traditional, target-orientated approaches in drug discovery programs. With improved access to primary cells, as well as label-free, non-intrusive methods of compound interrogation (such ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.02.010

    authors: Möller C,Slack M

    更新日期:2010-05-01 00:00:00

  • Catabolic mediators as targets for cancer cachexia.

    abstract::The cachexia syndrome, characterized by a marked weight loss, anorexia, asthenia and anaemia, is invariably associated with the growth of a tumour and leads to a malnutrition status caused by the induction of anorexia or decreased food intake. In addition, the competition for nutrients between the tumour and the host ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(03)02826-5

    authors: Argilés JM,Moore-Carrasco R,Busquets S,López-Soriano FJ

    更新日期:2003-09-15 00:00:00

  • Emerging high-throughput drug target validation technologies.

    abstract::Identifying the right target for drug development is a critical bottleneck in the pharmaceutical and biotech industries. The genomics revolution has shifted the problem from a scarcity of targets to a surplus of putative drug targets. As the validity of a target cannot be simply inferred from correlative data, the key...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(02)02429-7

    authors: Ilag LL,Ng JH,Beste G,Henning SW

    更新日期:2002-09-15 00:00:00

  • Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?

    abstract::The growing application of nanomaterials in healthcare products (i.e., cosmetics, medical devices, and medicinal products) has encouraged the upgrade of the regulatory framework within the European Community to better control their use and manage the risk of negative effects on human health and environment. Unfortunat...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.016

    authors: Musazzi UM,Marini V,Casiraghi A,Minghetti P

    更新日期:2017-06-01 00:00:00

  • Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach?

    abstract::The energy substrate preference of the human heart is well regulated and is modified upon aging, in that the fetal heart uses glucose, whereas the adult heart utilizes fatty acids. Various human and animal studies suggest a shift in myocardial substrate utilization and decreased rate of myocardial fatty acid uptake an...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.02.010

    authors: Arumugam S,Sreedhar R,Thandavarayan RA,Karuppagounder V,Watanabe K

    更新日期:2016-06-01 00:00:00

  • Mammalian carboxylesterases: from drug targets to protein therapeutics.

    abstract::Our understanding of the detailed recognition and processing of clinically useful therapeutic agents has grown rapidly in recent years, and we are now able to begin to apply this knowledge to the rational treatment of disease. Mammalian carboxylesterases (CEs) are enzymes with broad substrate specificities that have k...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03383-0

    authors: Redinbo MR,Potter PM

    更新日期:2005-03-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01533-6

    authors: Lloyd AW

    更新日期:2000-08-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01877-3

    authors: Barlocco D,Langston S,Tranter D

    更新日期:2001-08-01 00:00:00

  • What is precise pathophysiology in development of hypertension in pregnancy? Precision medicine requires precise physiology and pathophysiology.

    abstract::It is widely accepted that placental ischemia is central in the evolution of hypertension in pregnancy. Many studies and reviews have targeted placental ischemia to explain mechanisms for initiating pregnancy hypertension. The placenta is rich in blood vessels, which are the basis for developing placental ischemia. Ho...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.021

    authors: Gao Q,Tang J,Li N,Liu B,Zhang M,Sun M,Xu Z

    更新日期:2018-02-01 00:00:00

  • Translational strategies for development of monoclonal antibodies from discovery to the clinic.

    abstract::Successful strategies for the development of monoclonal antibodies require integration of knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, Fc domain engineering, PK/PD properties and antibody cross-reactivity across species from the early stages of anti...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.12.008

    authors: Tabrizi MA,Bornstein GG,Klakamp SL,Drake A,Knight R,Roskos L

    更新日期:2009-03-01 00:00:00

  • Genomic microarrays in the spotlight.

    abstract::Microarray-based comparative genomic hybridization (array-CGH) has emerged as a revolutionary platform, enabling the high-resolution detection of DNA copy number aberrations. In this article we outline the use and limitations of genomic clones, cDNA clones and PCR products as targets for genomic microarray constructio...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:

    authors: Mantripragada KK,Buckley PG,de Ståhl TD,Dumanski JP

    更新日期:2004-12-15 00:00:00

  • Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.

    abstract::Drug-induced rhabdomyolysis (DIR) is an idiosyncratic and fatal adverse drug reaction (ADR) characterized in severe muscle injuries accompanied by multiple-organ failure. Limited knowledge regarding the pathophysiology of rhabdomyolysis is the main obstacle to developing early biomarkers and prevention strategies. Giv...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.06.006

    authors: Wen Z,Liang Y,Hao Y,Delavan B,Huang R,Mikailov M,Tong W,Li M,Liu Z

    更新日期:2019-01-01 00:00:00

  • Recombinant high-density lipoproteins and their use in cardiovascular diseases.

    abstract::The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.08.010

    authors: Cao YN,Xu L,Han YC,Wang YN,Liu G,Qi R

    更新日期:2017-01-01 00:00:00

  • Revival of the regulatory T cell: new targets for drug development.

    abstract::Compelling new evidence supports the idea that regulatory T cells play a major role in our immune system. Several subsets of these regulators have been identified recently. Differences in the phenotypical and functional characteristics of these subsets have immunological implications. From our growing knowledge of the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)03021-6

    authors: Sutmuller RP,Offringa R,Melief CJ

    更新日期:2004-04-01 00:00:00

  • Expanding medicinal chemistry space.

    abstract::Clinically useful drugs target a relatively small number of proteins that lie within a clearly defined and chemically accessible space. However, many high value biological targets lie outside this chemical space, and an ability to access such 'intractable' targets not amenable to traditional small molecule interventio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.10.008

    authors: Barker A,Kettle JG,Nowak T,Pease JE

    更新日期:2013-03-01 00:00:00

  • p53 family interactions and yeast: together in anticancer therapy.

    abstract::The p53 family proteins are among the most appealing targets for cancer therapy. A deeper understanding of the complex interplay that these proteins establish with murine double minute (MDM)2, MDMX, and mutant p53 could reveal new exciting therapeutic opportunities in cancer treatment. Here, we summarize the most rele...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.02.007

    authors: Gomes S,Leão M,Raimundo L,Ramos H,Soares J,Saraiva L

    更新日期:2016-04-01 00:00:00

  • Drug discovery for enzymes.

    abstract::Enzymes are essential, physiological catalysts involved in all processes of life, including metabolism, cellular signaling and motility, as well as cell growth and division. They are attractive drug targets because of the presence of defined substrate-binding pockets, which can be exploited as binding sites for pharma...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2021.01.006

    authors: Rufer AC

    更新日期:2021-01-14 00:00:00

  • Pharmaceutical approaches to the treatment of obesity.

    abstract::The recent increase in pharmaceutical companies' efforts toward the treatment of obesity reflects recognition of the related health risks, the growth of knowledge about mechanisms that control energy balance, and the potential market for new compounds. The current patent literature gives a picture of the targets that ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03244-1

    authors: Jandacek RJ,Woods SC

    更新日期:2004-10-15 00:00:00

  • Pharmacotherapy for metabolic and cellular stress in degenerative retinal diseases.

    abstract::Retinal photoreceptors continually endure stresses associated with prolonged light exposure and the metabolic demands of dark adaptation. Although healthy photoreceptors are able to withstand these stresses for several decades, the disease-affected retina functions at a reduced capacity and is at an increased risk for...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.013

    authors: Kubota R,Gregory J,Henry S,Mata NL

    更新日期:2020-02-01 00:00:00

  • Understanding the checkpoint blockade in lung cancer immunotherapy.

    abstract::Immunotherapies have changed the treatment strategy of some types of tumor including melanoma and, more recently, non-small-cell lung cancer (NSCLC). Immune checkpoints are crucial for the maintenance of self-tolerance and it is known that some tumors use checkpoint systems to evade antitumor immune response. The trea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.05.016

    authors: Dal Bello MG,Alama A,Coco S,Vanni I,Grossi F

    更新日期:2017-08-01 00:00:00

  • Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation.

    abstract::In recent years there has been a dramatic increase in the number of freely accessible online databases serving the chemistry community. The internet provides chemistry data that can be used for data-mining, for computer models, and integration into systems to aid drug discovery. There is however a responsibility to en...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.013

    authors: Williams AJ,Ekins S,Tkachenko V

    更新日期:2012-07-01 00:00:00

  • Current and emerging treatment options for spinal cord ischemia.

    abstract::Spinal cord infarction (SCI) is a rare but disabling disorder caused by a wide spectrum of conditions. Given the lack of randomized-controlled trials, contemporary treatment concepts are adapted from guidelines for cerebral ischemia, atherosclerotic vascular disease, and acute traumatic spinal cord injury. In addition...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.06.015

    authors: Nardone R,Pikija S,Mutzenbach JS,Seidl M,Leis S,Trinka E,Sellner J

    更新日期:2016-10-01 00:00:00

  • Molecular perspectives on solid-state phase transformation and chemical reactivity of drugs: metoclopramide as an example.

    abstract::Here, I provide an overview of the solid-state characteristics, phase transformations and chemical reactions of metoclopramide hydrochloride monohydrate (MCP HCl H2O). Three unique techniques, including thermoanalytical methods, one-step simultaneous differential scanning calorimetry (DSC) and Fourier transform infrar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.10.001

    authors: Lin SY

    更新日期:2015-02-01 00:00:00